ORAMED PHARMACEUTICALS INC.
For the period ended Jun 30, 2026. Filed Aug 10, 2026.
View on SEC.govAbout this filing
A company's report for each of its first three quarters. The financial statements are not audited. It shows how the business has moved since the last annual report, and what management says changed.
Jun 30, 2026 · Filed Aug 10, 2026
ORMP$3.97-0.7%Stored close · as of Nov 10, 2026
Extracted filing text, with the paragraph anchors used by the comparison.
See the whole filing, with its images and exhibitsContents
Condensed Consolidated Statements of Cash Flows
INTERIM CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS
U.S. dollars in thousands
| Six months ended June 30, | |||
|---|---|---|---|
| 2026 · 2025 | |||
| CASH FLOWS FROM OPERATING ACTIVITIES: | |||
| Net income | $116,466 | $5,618 | |
| Adjustments required to reconcile net income to net cash used in operating activities: | |||
| Depreciation | 61 | 60 | |
| Exchange differences and interest on deposits | 127 | (73) | |
| Changes in fair value of investments | (148,467) | (11,429) | |
| Stock-based compensation | 3,129 | 2,989 | |
| Gain on amounts funded in respect of employee rights upon retirement | (5) | (6) | |
| Gain on sale of IP | (5,821) | - | |
| Deferred Taxes | 31,633 | - | |
| Changes in operating assets and liabilities: | |||
| Prepaid expenses and other current assets | 1,364 | 816 | |
| Accounts payable, accrued expenses and related parties | 1,031 | (3,280) | |
| Net changes in operating lease | 41 | 72 | |
| Deferred revenues | (2,000) | (2,000) | |
| Deferred income | (678) | 233 | |
| Liability for employee rights upon retirement | 4 | 6 | |
| Other liabilities | - | (60) | |
| Total net cash used in operating activities | (3,115) | (7,054) | |
| CASH FLOWS FROM INVESTING ACTIVITIES: | |||
| Purchase of non-marketable securities | (500) | - | |
| Purchase of marketable securities | (21,588) | - | |
| Proceeds from marketable securities | 10,605 | 1,049 | |
| Investments at fair value | (6,735) | (63,571) | |
| Proceeds from redemption of short-term deposits | 10,948 | 32,450 | |
| Proceeds from loan to an equity method investee | - | 3,442 | |
| Loan to investment in equity method | - | (7,000) | |
| Real estate investment | - | (1,949) | |
| Equity method investee | - | (250) | |
| Lifeward transaction | (11,924) | - | |
| Proceeds from investments | 4,023 | 4,599 | |
| Purchase of property and equipment | (7) | (7) | |
| Total net cash used in investing activities | (15,178) | (31,237) | |
| CASH FLOWS FROM FINANCING ACTIVITIES: | |||
| Repurchase and retirement of common stock | - | (371) | |
| Tax withholdings related to stock-based compensation settlements | (1,871) | - | |
| Dividend paid | (10,442) | - | |
| Total net cash used in financing activities | (12,313) | (371) | |
| EFFECT OF EXCHANGE RATE CHANGES ON CASH AND CASH EQUIVALENTS | (96) | 39 | |
| DECREASE IN CASH AND CASH EQUIVALENTS | (30,702) | (38,623) | |
| CASH AND CASH EQUIVALENTS AT BEGINNING OF PERIOD | 45,947 | 54,420 | |
| CASH AND CASH EQUIVALENTS AT END OF PERIOD | $15,245 | $15,797 | |
| (A) SUPPLEMENTARY DISCLOSURE ON CASH FLOWS - | |||
| Interest received | $642 | $1,352 | |
| Taxes paid on income | $ | - | $3,318 |
| (B) SUPPLEMENTAL DISCLOSURE OF NON-CASH ACTIVITIES - | |||
| Investment in investee | - | 390 | |
| Investment in associate at fair value- Lifeward | 6,796 | - | |
| Forfeited dividends | 5 | - | |
| Recognition of operating lease right-of-use assets and liabilities | - | 602 | |
| Warrants received from Alpha Tau | - | 2,727 | |
The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.